Vighnesh Bharath1, Kathleen Eckert2, Matthew Kang3, Ian H Chin-Yee3,4, Cyrus C Hsia3. 1. Department of Medicine, London Health Sciences Centre, Victoria Hospital. 2. Blood Transfusion Laboratory, London Health Sciences Centre, Victoria Hospital. 3. Division of Hematology, Department of Medicine, London Health Sciences Centre, Victoria Hospital. 4. Canadian Blood Services, London, Ontario, Canada.
Abstract
BACKGROUND: Aseptic meningitis is a rare but significant complication of intravenous immunoglobulin (IVIG) therapy. The majority of literature is limited to case reports, so the true incidence of this complication is uncertain. STUDY DESIGN AND METHODS: A retrospective review of all cases of IVIG-associated adverse transfusion reactions was performed at London Health Sciences Centre (LHSC) from January 1, 2008, to December 31, 2013. All reported transfusion reactions were evaluated to identify cases of aseptic meningitis due to IVIG. All documented IVIG infusions and lumbar punctures performed during the study period were reviewed; patients with both interventions were identified and further chart review was performed to identify aseptic meningitis. RESULTS: During our study period, 1324 unique patients received a total of 11,907 IVIG infusions (554,566 g) for various conditions. Eight cases of aseptic meningitis were identified, suggesting an overall incidence of 0.60% for all patients and 0.067% for all IVIG infusions. Patients presented with symptoms within 24 to 48 hours of the infusion and were treated with antibiotics initially. The reactions were self-limited, as symptoms self-resolved within 5 to 7 days. Treatment was supportive, with subsequent IVIG infusions likely requiring preinfusion medication or possibly a switch in product formulation. CONCLUSION: This review of IVIG-induced aseptic meningitis over a 6-year period identifies a more robust estimate of incidence and risk of 0.60% and 0.067% for all patients and infusions, respectively. Given that this complication can mimic infectious meningitis and cause considerable morbidity, physicians need to be aware of this rare but important condition.
BACKGROUND:Aseptic meningitis is a rare but significant complication of intravenous immunoglobulin (IVIG) therapy. The majority of literature is limited to case reports, so the true incidence of this complication is uncertain. STUDY DESIGN AND METHODS: A retrospective review of all cases of IVIG-associated adverse transfusion reactions was performed at London Health Sciences Centre (LHSC) from January 1, 2008, to December 31, 2013. All reported transfusion reactions were evaluated to identify cases of aseptic meningitis due to IVIG. All documented IVIG infusions and lumbar punctures performed during the study period were reviewed; patients with both interventions were identified and further chart review was performed to identify aseptic meningitis. RESULTS: During our study period, 1324 unique patients received a total of 11,907 IVIG infusions (554,566 g) for various conditions. Eight cases of aseptic meningitis were identified, suggesting an overall incidence of 0.60% for all patients and 0.067% for all IVIG infusions. Patients presented with symptoms within 24 to 48 hours of the infusion and were treated with antibiotics initially. The reactions were self-limited, as symptoms self-resolved within 5 to 7 days. Treatment was supportive, with subsequent IVIG infusions likely requiring preinfusion medication or possibly a switch in product formulation. CONCLUSION: This review of IVIG-induced aseptic meningitis over a 6-year period identifies a more robust estimate of incidence and risk of 0.60% and 0.067% for all patients and infusions, respectively. Given that this complication can mimic infectious meningitis and cause considerable morbidity, physicians need to be aware of this rare but important condition.
Authors: Robert W Foley; Nathan T Tagg; Matthew K Schindler; Kaylan M Fenton; Daniel S Reich; Irene Cortese; Ellen M Mowry Journal: Mult Scler Date: 2017-06-22 Impact factor: 6.312
Authors: Stefania Leuci; Noemi Coppola; Tiziana Cantile; Elena Calabria; Laurenta Lelia Mihai; Michele Davide Mignogna Journal: Int J Environ Res Public Health Date: 2022-03-25 Impact factor: 3.390
Authors: Timothy A Erickson; Flor M Munoz; Catherine L Troisi; Melissa S Nolan; Rodrigo Hasbun; Eric L Brown; Kristy O Murray Journal: Microorganisms Date: 2021-03-04